HIGHNOON LABORATORIES LIMITED |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 529 PKR | -0.79% |
|
-7.97% | +4.84% |
| Sales 2022 | 15.82B 56.84M | Sales 2023 | 19.77B 71.04M | Capitalization | 26.73B 96.08M |
|---|---|---|---|---|---|
| Net income 2022 | 2.47B 8.89M | Net income 2023 | 2.45B 8.8M | EV / Sales 2022 | 1.38 x |
| Net cash position 2022 | 838M 3.01M | Net cash position 2023 | 878M 3.16M | EV / Sales 2023 | 1.31 x |
| P/E ratio 2022 |
9.15
x | P/E ratio 2023 |
10.9
x | Employees | 2,295 |
| Yield 2022 |
3.7% | Yield 2023 |
5.95% | Free-Float | 48.45% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -0.79% | ||
| 1 week | -7.97% | ||
| Current month | +3.83% | ||
| 1 month | +3.88% | ||
| 3 months | +3.72% | ||
| 6 months | +27.76% | ||
| Current year | +4.84% |
1 week
520.00
570.00
1 month
503.00584.00
Current year
465.50584.00
1 year
322.10584.00
3 years
322.10584.00
5 years
130.66584.00
10 years
48.76584.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | - | |
| Director of Finance/CFO | - | 20-03-31 | |
Ali Sarwar
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Tariq Wajid
BRD | Director/Board Member | - | 23-02-23 |
| Chairman | - | 83-12-31 | |
| Director/Board Member | - | 88-02-29 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 529 | -0.79% | 10,970 |
| 24-04-18 | 533.2 | -5.71% | 26,499 |
| 24-04-17 | 565.4 | +0.90% | 8,305 |
| 24-04-16 | 560.4 | -1.05% | 14,462 |
End-of-day quote Pakistan S.E., April 18, 2024
More quotes
Highnoon Laboratories Limited is a Pakistan-based company that is engaged in the manufacturing, importing, selling and marketing of pharmaceutical and allied consumer products. The Company's product categories include cardiology, metabolic, gastroenterology, musculoskeletal, anti-infective, obstetrics and gynecology, pediatrics, allergy, respiratory, and urology. Its cardiology products include Somno, Hitica, Apiban, Pidogrel-AP, Blokium DIU, Epliron, Sacuvia, Ivaset, Rivaro, Valforge and Herbesser. Its metabolic products include Xormet XR, MetFormin HCI, Diajard-MXR, Diajard-M and Diajard. The Company's gastroenterology products include Liv 52, Rabecid and Racedo. Its musculoskeletal products include Flexa Plus, Airtal ER and Tamadol. The Company's pediatric products include Bonisan, Cogniza, Flu Ace, Prospan and Tres Orix Forte. Its allergy products include Leviva and Kestine. Its Respiratory products include Combivair Forte, Sprahaler Respules, Foracort HFA Inhaler and Rotaflo.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| +4.84% | 101M | |
| +24.60% | 654B | |
| +24.08% | 552B | |
| -5.63% | 356B | |
| +15.37% | 319B | |
| +7.38% | 295B | |
| +3.26% | 211B | |
| +0.78% | 206B | |
| -9.16% | 197B | |
| -9.69% | 147B |
- Stock Market
- Equities
- HINOON Stock
